FI963196A0 - Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö - Google Patents

Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö

Info

Publication number
FI963196A0
FI963196A0 FI963196A FI963196A FI963196A0 FI 963196 A0 FI963196 A0 FI 963196A0 FI 963196 A FI963196 A FI 963196A FI 963196 A FI963196 A FI 963196A FI 963196 A0 FI963196 A0 FI 963196A0
Authority
FI
Finland
Prior art keywords
melanoma
peptides recognized
specific
lymphocytes
cytoxic lymphocytes
Prior art date
Application number
FI963196A
Other languages
English (en)
Swedish (sv)
Other versions
FI963196A (fi
Inventor
Craig L Slingluff
Victor H Engelhard
Donald F Hunt
Jeffrey Shabanowitz
Andrea L Cox
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI963196(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of FI963196A0 publication Critical patent/FI963196A0/fi
Publication of FI963196A publication Critical patent/FI963196A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI963196A 1994-02-16 1996-08-15 Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö FI963196A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19739994A 1994-02-16 1994-02-16
US08/234,784 US6660276B1 (en) 1994-02-16 1994-04-29 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
PCT/US1995/001991 WO1995022561A2 (en) 1994-02-16 1995-02-16 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor

Publications (2)

Publication Number Publication Date
FI963196A0 true FI963196A0 (fi) 1996-08-15
FI963196A FI963196A (fi) 1996-10-15

Family

ID=26892817

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963196A FI963196A (fi) 1994-02-16 1996-08-15 Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö

Country Status (9)

Country Link
US (1) US6660276B1 (fi)
EP (1) EP0745095A1 (fi)
AU (1) AU701531B2 (fi)
CA (1) CA2182889C (fi)
FI (1) FI963196A (fi)
MX (1) MX9603431A (fi)
NO (1) NO963344L (fi)
NZ (1) NZ282183A (fi)
WO (1) WO1995022561A2 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (en) 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US6613530B1 (en) 1994-07-25 2003-09-02 Roche Diagnostics Gmbh Determination of a specific immunoglobulin using multiple antigens
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
AU1394497A (en) * 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
AU712820B2 (en) * 1996-03-19 1999-11-18 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytotoxic lymphocytes, and uses therefor
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
US20080274129A1 (en) 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
ATE546153T1 (de) * 2003-06-17 2012-03-15 Mannkind Corp Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
WO2006037059A2 (en) 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Point-of-care mass spectrometer system
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
AU2007222080B2 (en) * 2006-03-01 2012-08-16 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with CTLs and cytokines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119760B2 (ja) 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
AU6496094A (en) 1993-03-31 1994-10-24 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5472856A (en) * 1993-12-21 1995-12-05 Immunobiology Research Institute, Inc. Recombinant human thymopoietin proteins and uses therefor
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
WO1995022561A3 (en) 1996-03-07
CA2182889C (en) 2008-12-23
NZ282183A (en) 1998-07-28
US6660276B1 (en) 2003-12-09
EP0745095A1 (en) 1996-12-04
AU1921595A (en) 1995-09-04
CA2182889A1 (en) 1995-08-24
AU701531B2 (en) 1999-01-28
WO1995022561A2 (en) 1995-08-24
MX9603431A (es) 1997-03-29
FI963196A (fi) 1996-10-15
NO963344D0 (no) 1996-08-09
NO963344L (no) 1996-10-14

Similar Documents

Publication Publication Date Title
EE03427B1 (et) Pihusti sõlm ja selle kasutamine
EE9700209A (et) Dihüdropürimidiinid ja nende kasutamine
FI963196A0 (fi) Melanoomaspesifisten sytoksisten lymfosyyttien tunnistamia peptidejä ja niiden käyttö
ATE151622T1 (de) Nasaler dilatator
DK0941056T3 (da) Sphingomyelinasepræparater samt anvendelse deraf
IT1273501B (it) Snodo omocinetico
BR9606984A (pt) Vassoura e conjunto de vassoura
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
FR2726869B1 (fr) Joint homocinetique
BR9610109A (pt) Fecho e uso mesmo
IS4459A (is) Ný peptíð er hafa ónæmisbreytandi áhrif
FI970168A0 (fi) Peptidejä
DE59507901D1 (de) Einspritzdüse
ID19147A (id) Ksilanase dan pemakaiannya
BR9509688A (pt) Composto e composição farmacêutica
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE59502382D1 (de) Einspritzventil
FI963164A (fi) Diabeteksen vastaisia peptidejä ja menetelmä
KR960010685A (ko) 펩티드 및 그 용도
FI950561A (fi) Ryömykestävä rauta-kromi-alumiiniseos ja siitä valmistettu tuote
FR2723991B1 (fr) Joint homocinetique
BR9505130A (pt) Composto e composiçao farmacêutica
ID17395A (id) Aluminosilikat berbentuk beraturan dan penggunaannya
DE9411920U1 (de) Auftragstift
KR950033675U (ko) 못